Aptevo and Niowave launch 50/50 radiopharmaceutical collaboration with 7.9% equity stake

Aptevo Therapeutics and Niowave announced a strategic partnership to develop up to three radiopharmaceutical oncology programs, with Niowave making an at-the-market equity investment representing 7.9% ownership and potential to reach 19.99% through warrants. The collaboration combines Aptevo's multispecific antibody platforms with Niowave's radioisotope production capabilities to address supply constraints and develop new oncology treatments.